Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Letters

Pertussis control in Canada

Scott A. Halperin
CMAJ May 27, 2003 168 (11) 1389-1390;
Scott A. Halperin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

The outbreak of pertussis in a refinery as described by John Hoey in a recent article on pertussis in adults1 is interesting but pales in comparison with outbreaks recently reported from Vancouver Island, where well over 100 positive cases (by both culture and polymerase chain reaction) were diagnosed in adolescents and adults,2 and from Quebec, where the severity of pertussis in older adults was well characterized.3 Rarely, pertussis can lead to severe complications, even in a healthy adult.4

The case-fatality rate of 0.8% reported by Hoey actually represents cases in infants under 2 years of age admitted to hospital.5 The overall case fatality rate is unknown but is undoubtedly lower.

There are a number of differences between the United States and Canada in recommendations for treatment and chemoprophylaxis of pertussis contacts. In Canada, treatment and chemoprophylaxis with erythromycin are recommended for 10 days rather than 14, and the maximum daily dose is 1 g rather than 2 g.6 Also, chemoprophylaxis is recommended in this country only in households or other environments where there is an infant under 1 year of age. Canadian guidelines will soon be revised according to the recommendations of the National Consensus Conference on Pertussis (held in May 2002). On the basis of results from 4 randomized controlled trials, the recommended treatment for pertussis will be 7 days of erythromycin,7 5 days of azithromycin8 or 7 days of clarithromycin,9 and chemoprophylaxis will be limited to households with an infant under 1 year of age (because of lack of benefit in modifying the development of clinical disease in contacts10).

The recommendations for vaccination presented by Hoey were those of the US Centers for Disease Control and Prevention. In Canada, an adolescent/adult formulation of acellular pertussis vaccine combined with diphtheria and tetanus toxoids (known by the abbreviation TdaP; Adacel, Aventis Pasteur) is licensed for use in people 12 to 50 years of age. The National Advisory Committee on Immunization recommends that all adolescents receive TdaP in place of Td.11 More extensive use of this vaccine beyond adolescence may be beneficial in controlling the increasing burden of disease in adults.

Scott A. Halperin Head, Pediatric Infectious Diseases Dalhousie University IWK Health Centre Halifax, NS

References

  1. 1.↵
    Hoey J. Pertussis in adults. CMAJ 2003;168 (4): 453-4.
    OpenUrlFREE Full Text
  2. 2.↵
    Skowronski DM, De Serres G, MacDonald D, Wu W, Shaw C, Macnabb J, et al. The changing age and seasonal profile of pertussis in Canada. J Infect Dis 2002;185:1448–53.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    De Serres G, Shadmani R, Duval B, Boulianne N, Déry P, Fradet MD, et al. Morbidity of pertussis in adolescents and adults. J Infect Dis 2000; 182: 174–9.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    Skowronski DM, Buxton JA, Hestrin M, Keyes RD, Lynch K, Halperin SA. Carotid artery dissection as a possible severe complication of pertussis in an adult: clinical case report and review. Clin Infect Dis 2003;36:e1–4.
  5. 5.↵
    Halperin SA, Wang EL, Law B, Mills E, Morris R, Déry P, et al. Epidemiological features of pertussis in hospitalized patients in Canada, 1991–1997: report of the Immunization Monitoring Program–Active (IMPACT). Clin Infect Dis 1999;28:1238–43.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    National Advisory Committee on Immunization, Advisory Committee on Epidemiology, and Canadian Paediatric Society. Statement on management of persons exposed to pertussis and pertussis outbreak control. Can Commun Dis Rep 1994; 20: 193-9.
    OpenUrlPubMed
  7. 7.↵
    Halperin SA, Bortolussi R, Langley J, Miller B, Eastwood B. Seven days of erythromycin estolate is as effective as fourteen days for the treatment of Bordetella pertussis infections. Pediatrics 1997; 100:65–71.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    Halperin SA, Langley JM, Boucher FD, Smith B. Azithromycin is as effective as and better tolerated than erythromycin estolate for the treatment of pertussis [abstract 169]. 40th annual meeting of Infectious Diseases Society of America; 2002 Oct 24–27; Chicago.
  9. 9.↵
    Lebel MH, Mehra S. Efficacy and safety of clarithromycin versus erythromycin for the treatment of pertussis: a prospective, randomized, single blind trial. Pediatr Infect Dis J 2001;20: 1149-54.
    OpenUrlCrossRefPubMed
  10. 10.↵
    Halperin SA, Bortolussi R, Langley JM, Eastwood BJ, De Serres G. A randomized, placebo-controlled trial of erythromycin estolate chemoprophylaxis for household contacts of children with culture-positive Bordetella pertussis infection. Pediatrics 1999;104(4):e42. Available: www.pediatrics.org/cgi/content/full/104/4/e42 (accessed 2003 Apr 9).
  11. 11.↵
    National Advisory Committee on Pertussis. Pertussis. In: Canadian immunization guide. 6th ed. Ottawa: Canadian Medical Association; 2002. p. 169-76.
PreviousNext
Back to top

In this issue

CMAJ
Vol. 168, Issue 11
27 May 2003
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Pertussis control in Canada
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Pertussis control in Canada
Scott A. Halperin
CMAJ May 2003, 168 (11) 1389-1390;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Pertussis control in Canada
Scott A. Halperin
CMAJ May 2003, 168 (11) 1389-1390;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Hospital-at-home programs in Canada: challenges and pitfalls
  • Author response to “Pitfalls of analyzing perinatal outcomes by health care provider”
  • Pitfalls of analyzing perinatal outcomes by health care provider
Show more Letters

Similar Articles

Collections

  • Topics
    • Public health
    • Respiratory medicine

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

CMA Civility, Accessibility, Privacy

 

Powered by HighWire